Evidence map›Paper›PMID 26672090›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2016

Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC.

Paul Drawz, Sabarish Ayyappan, Mehdi Nouraie, Santosh Saraf, Victor Gordeuk, Thomas Hostetter, Mark T Gladwin, Jane Little

Abstract readComparative Study
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Hydroxyurea (hydroxycarbamide) for sickle cell disease.The Cochrane database of systematic reviews · 2022
    Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Observational
  7. Review
  8. Article
  9. Article
  10. Article
  11. Management of Kidney Disease with Sickle Cell Disease.Journal of the American Society of Nephrology : JASN · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Paul DrawzDivision of Renal Diseases and Hypertension, University of Minnesota, Minneapolis, Minnesota;
Sabarish AyyappanDivisions of Hematology and Oncology, and.
Mehdi NouraieCenter for Sickle Cell Disease, Howard University, Washington, DC;
Santosh SarafDivision of Hematology/Oncology, University of Illinois, Chicago, Illinois; and.
Victor GordeukComprehensive Sickle Cell Center.
Thomas HostetterNephrology and Hypertension,University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio;
Mark T GladwinVascular Medicine Institute and Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Jane LittleDivisions of Hematology and Oncology, and Jane.Little@uhhospitals.org.
Palmetto Hematology Oncology · USHoward University · USUniversity Hospitals of Cleveland · USUniversity of Illinois Chicago · USUniversity of Minnesota · USUniversity of Pittsburgh · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
Center for Hemoglobin Research in Minorities (CHaRM)P50HL118006 · NHLBI · HOWARD UNIVERSITY · PI NEKHAI, SERGEI · 2013 to 2017
$7.0M
Genetics and Genomics of Sickle Cell Nephropathy.K23HL125984 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARAF, SANTOSH · 2015 to 2018
$700k
NCATS NIH HHS UL1 TR000114NHLBI NIH HHS K23 HL125984NHLBI NIH HHS P50 HL118006NHLBI NIH HHS P50HL118006
6 · The paper itself

Abstract

BACKGROUND AND

objectivesSickle cell disease (SCD) is an inherited anemia that afflicts millions worldwide. Kidney disease is a major contributor to its morbidity and mortality. We examined contemporary and historical SCD populations to understand how renal disease behaved in hemoglobin SS (HbSS) compared with HbSC. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Kidney function was examined in the multicentered Treatment of Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Therapy (Walk-PHaSST) Trial (HbSS=463; HbSC=127; years 2007-2009) and historical comparator populations from the Cooperative Study of Sickle Cell Disease (CSSCD; HbSS=708) and the Multicenter Study of Hydroxyurea in Sickle Cell Disease (MSH; HbSS=299).

resultsIn adults with SCD, eGFR was lower among older individuals: -1.78 ml/min per 1.73 m(2) per year of age (95% confidence interval [95% CI], -2.06 to -1.50; Walk-PHaSST Trial), -1.75 ml/min per 1.73 m(2) per year of age (95% CI, -2.05 to -1.44; MSH), and -1.69 ml/min per 1.73 m(2) per year of age (95% CI, -2.00 to -1.38; CSSCD) in HbSS compared with -1.09 ml/min per 1.73 m(2) per year of age (95% CI, -1.39 to -0.75) in HbSC (Walk-PHaSST Trial). Macroalbuminuria was seen in 20% of participants with SCD (HbSS or HbSC; P=0.45; Walk-PHaSST Trial), but microalbuminuria was more prevalent in HbSS (44% versus 23% in HbSC; P<0.002). In the Walk-PHaSST Trial, albuminuria was associated with hemolysis (higher lactate dehydrogenase, P<0.001; higher absolute reticulocyte count, P<0.02; and lower Hb, P=0.07) and elevated systolic BP (P<0.001) in HbSS. One half of all participants with HbSS (20 of 39) versus one fifth without (41 of 228) elevated tricuspid regurgitant jet velocity (≥3 m/s; adverse prognostic indicator in SCD) had macroalbuminuria (P<0.001). In the CSSCD, overt proteinuria, detected (less sensitively) by urine dipstick, associated with higher 3-year mortality (odds ratio, 2.48; 95% CI, 1.07 to 5.77). Serum bicarbonate was lower in HbSS (23.8 versus 24.8 mEq/dl in HbSC; P<0.05) and associated with reticulocytopenic anemia and decreased renal function.

conclusionsIn SCD, albuminuria or proteinuria was highly prevalent, in HbSS more than in HbSC. Proteinuria associated with mortality in HbSS. Older individuals had a lower than expected eGFR, and this was more prominent in HbSS. Current management does not routinely address renal complications in SCD, which could plausibly reduce morbidity and mortality.

Indexed as

Acid-Base EquilibriumAdultAlbuminuriaAnemia, Sickle CellBiomarkersClinical Trials as TopicFemaleGlomerular Filtration RateHemoglobin CHemoglobin SC DiseaseHemoglobin, SickleHistorically Controlled StudyHumansKidneyKidney DiseasesMaleBiomarkersHemoglobin CHemoglobin, Sickleacidosisalbuminuriaanemia, sickle cellblood pressurechronic kidney diseaseglomerular filtration ratehumanshydroxyureahypertension, pulmonary

Identifiers

PMID26672090
PMCPMC4741034
OpenAlexW2272752585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.